Literature DB >> 25098285

Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.

Miguel F Sanmamed1, Lieping Chen.   

Abstract

Immune evasion is an important hallmark of cancer, and a better understanding of this mechanism is essential for the development of effective strategies against cancer. The B7 homolog 1 (B7-H1)/programmed cell death 1 (PD-1) pathway has been demonstrated as a major mechanism of immune evasion in tumor site, and its blockade therapy shows very encouraging results in clinical trials. Inducible B7-H1 expression in tumor microenvironment is complex, with multidimensional interactions and expression by different subsets of hematopoietic and nonhematopoietic cells. Understanding these interactions and how tumors take advantage of this pathway can help us design future strategies for better therapeutic efficacy and to overcome resistances.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25098285      PMCID: PMC4455021          DOI: 10.1097/PPO.0000000000000061

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  50 in total

1.  Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.

Authors:  Elias A Said; Franck P Dupuy; Lydie Trautmann; Yuwei Zhang; Yu Shi; Mohamed El-Far; Brenna J Hill; Alessandra Noto; Petronela Ancuta; Yoav Peretz; Simone G Fonseca; Julien Van Grevenynghe; Mohamed R Boulassel; Julie Bruneau; Naglaa H Shoukry; Jean-Pierre Routy; Daniel C Douek; Elias K Haddad; Rafick-Pierre Sekaly
Journal:  Nat Med       Date:  2010-03-07       Impact factor: 53.440

2.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors:  Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-09-27       Impact factor: 39.397

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

4.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

5.  The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

Authors:  Hazem Ghebeh; Shamayel Mohammed; Abeer Al-Omair; Amal Qattan; Cynthia Lehe; Ghofran Al-Qudaihi; Naser Elkum; Mohamed Alshabanah; Suad Bin Amer; Asma Tulbah; Dahish Ajarim; Taher Al-Tweigeri; Said Dermime
Journal:  Neoplasia       Date:  2006-03       Impact factor: 5.715

6.  Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Authors:  Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

7.  B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy.

Authors:  Nicole Selenko-Gebauer; Otto Majdic; Andreas Szekeres; Gerald Höfler; Elisabeth Guthann; Ulf Korthäuer; Gerhard Zlabinger; Peter Steinberger; Winfried F Pickl; Hannes Stockinger; Walter Knapp; Johannes Stöckl
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

10.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

View more
  60 in total

1.  Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.

Authors:  Tsuyoshi Hamada; Yin Cao; Zhi Rong Qian; Yohei Masugi; Jonathan A Nowak; Juhong Yang; Mingyang Song; Kosuke Mima; Keisuke Kosumi; Li Liu; Yan Shi; Annacarolina da Silva; Mancang Gu; Wanwan Li; NaNa Keum; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Edward L Giovannucci; Marios Giannakis; Scott J Rodig; Gordon J Freeman; Daniel Nevo; Molin Wang; Andrew T Chan; Charles S Fuchs; Reiko Nishihara; Shuji Ogino
Journal:  J Clin Oncol       Date:  2017-04-13       Impact factor: 44.544

2.  Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis.

Authors:  Xiaoyang Li; Yu Zheng; Fei Yue
Journal:  Target Oncol       Date:  2021-01       Impact factor: 4.493

3.  PHA eludes macrophage suppression to activate CD8+ T cells.

Authors:  Yelizavet D Lomakova; Jennifer Londregan; Jeffrey Maslanka; Naomi Goldman; John Somerville; James E Riggs
Journal:  Immunobiology       Date:  2018-11-03       Impact factor: 3.144

4.  Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma.

Authors:  Hulya Sahin Ozkan; Mustafa Umit Ugurlu; Perran Fulden Yumuk; Handan Kaya
Journal:  Pathol Oncol Res       Date:  2020-07-17       Impact factor: 3.201

5.  The Challenge for Development of Valuable Immuno-oncology Biomarkers.

Authors:  Janice M Mehnert; Arta M Monjazeb; Johanna M T Beerthuijzen; Deborah Collyar; Larry Rubinstein; Lyndsay N Harris
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

6.  Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

Authors:  Diwakar Davar; Hong Wang; Joe-Marc Chauvin; Ornella Pagliano; Julien J Fourcade; Mignane Ka; Carmine Menna; Amy Rose; Cindy Sander; Amir A Borhani; Arivarasan Karunamurthy; Ahmad A Tarhini; Hussein A Tawbi; Qing Zhao; Blanca H Moreno; Scott Ebbinghaus; Nageatte Ibrahim; John M Kirkwood; Hassane M Zarour
Journal:  J Clin Oncol       Date:  2018-10-25       Impact factor: 44.544

7.  TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.

Authors:  Tsuyoshi Hamada; Thing Rinda Soong; Yohei Masugi; Keisuke Kosumi; Jonathan A Nowak; Annacarolina da Silva; Xinmeng Jasmine Mu; Tyler S Twombly; Hideo Koh; Juhong Yang; Mingyang Song; Li Liu; Mancang Gu; Yan Shi; Katsuhiko Nosho; Teppei Morikawa; Kentaro Inamura; Sachet A Shukla; Catherine J Wu; Levi A Garraway; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Andrew T Chan; Jonathan N Glickman; Scott J Rodig; Gordon J Freeman; Charles S Fuchs; Reiko Nishihara; Marios Giannakis; Shuji Ogino
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

8.  Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy.

Authors:  Yu Zhang; Lieping Chen
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777

Review 9.  Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.

Authors:  Zhong-Yi Dong; Si-Pei Wu; Ri-Qiang Liao; Shu-Mei Huang; Yi-Long Wu
Journal:  Tumour Biol       Date:  2016-01-16

10.  EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3.

Authors:  Jaemoon Koh; Ji-Young Jang; Bhumsuk Keam; Sehui Kim; Moon-Young Kim; Heounjeong Go; Tae Min Kim; Dong-Wan Kim; Chul-Woo Kim; Yoon Kyung Jeon; Doo Hyun Chung
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.